Amgen (AMGN)
Technical, fundamental, and sentiment analysis with recent related videos.
AMGN rates Neutral overall. The fundamental read is neutral: the company passes 6 of 9 quality tests on the Piotroski F-Score; balance sheet is in the Grey zone (Altman Z = 2.13); revenue is growing about 11.9% per year; net income is growing about 17.3% per year. The technical picture is bullish: price is 19.2% above the 200-day moving average; 5.3% above the 50-day; the 50/200 relationship is in a Golden cross. Sentiment is bullish (composite 76/100), based on 8 news articles from recent coverage.
Revenue 3-year avg +11.9%. Net income 3-year avg +17.3%.
Price vs 20DMA +4.3%. RSI 60.85. Bollinger state: Inside Bands.
Composite score 76/100 from the AI judge, based on 8 news items, 0 television segments, and 0 videos.
Latest Market Read
Amgen’s badges split the picture: Fundamentals sit Neutral despite revenue averaging 11.9 percent per year and net income averaging 17.3 percent per year over three years. Technical is Bullish, the Relative Strength Index (RSI), a momentum reading, is 60.9 and the stock trades 4.3 percent above its 20-day moving average (the average closing price over the last 20 trading days), with price inside the Bollinger Bands (the volatility-based channel). Sentiment is Bullish at 76/100. The mix, bullish momentum and sentiment but neutral fundamentals, produces an overall Neutral rating.
Recent news: Coverage on the Phase III DELPHI-305/Imdelltra trial dominated headlines, with Global Database of Events, Language, and Tone (GDELT) articles and Internet Archive TV coverage highlighting IMFINZI plus Amgen’s tarlatamab cutting risk of death by 58 percent and improving survival, with several outlets calling it a breakthrough while noting regulatory review, the need for larger confirmation trials, and valuation and balance-sheet comparisons to J&J. Recent videos showed Amgen shares drifting lower in market-mover clips tied to CPI/PPI and S&P 500 noise.